Skip to main content
Beijing SL Pharmaceutical Co., Ltd. logo

Beijing SL Pharmaceutical Co., Ltd. — Investor Relations & Filings

Ticker · 002038 ISIN · CNE000001L31 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 1,472 across all filing types
Latest filing 2011-02-25 Annual Report
Country CN China
Listing Shenzhen Stock Exchange 002038

About Beijing SL Pharmaceutical Co., Ltd.

https://www.slpharm.com.cn

Beijing SL Pharmaceutical Co., Ltd. specializes in the research, development, manufacturing, and commercialization of pharmaceutical products. The company focuses on several therapeutic areas, including cardiovascular and cerebrovascular diseases, oncology, and infectious diseases. Its product portfolio features a range of chemical drugs and active pharmaceutical ingredients (APIs), with key offerings such as clopidogrel bisulfate and amlodipine besylate. Operating with advanced production facilities that adhere to international Good Manufacturing Practice (GMP) standards, the company emphasizes technological innovation and quality control. The organization serves both domestic and international markets, leveraging its integrated R&D platform to develop generic medications and innovative formulations aimed at improving patient outcomes.

Recent filings

Filing Released Lang Actions
2010年年度报告摘要
Annual Report Classification · 100% confidence The document is titled "北京双鹭药业股份有限公司 2010 年年度报告摘要" which translates to "Beijing SL Pharmaceutical Co., Ltd. 2010 Annual Report Summary." It contains detailed financial data for the year 2010, including revenue, profit, assets, shareholder information, management discussion and analysis, and future plans. The document references an audit report with an unqualified opinion, and it is a summary extracted from the full annual report. The length is substantial (15,000 characters), and it contains comprehensive financial and operational information typical of an annual report. Therefore, this document is the Annual Report itself, not just an announcement or a summary notice. Hence, the correct classification is Annual Report (10-K). FY 2010
2011-02-25 Chinese
规范与关联方资金往来管理制度（2011年2月）
Governance Information Classification · 95% confidence The document is a detailed internal policy document titled '规范与关联方资金往来管理制度' (Regulations on Management of Funds Transactions with Related Parties) issued by Beijing SL Pharmaceutical Co., Ltd. It outlines rules, procedures, responsibilities, and controls regarding financial dealings with related parties, including legal references, internal governance, audit management, and penalties for violations. There is no indication that this is an announcement, a report publication notice, or a certification. It is not a financial report like an annual or interim report, nor is it a regulatory filing or a legal proceeding update. It is a governance-related document detailing internal rules and procedures for managing related party transactions and funds. Therefore, it fits best under Governance Information (CGR). The document length is 3729 characters, which is relatively short but contains substantive governance content rather than a mere announcement or summary.
2011-02-25 Chinese
独立董事马清钧2010年度述职报告
Board/Management Information Classification · 95% confidence The document is a detailed annual report by an independent director of Beijing Shuanglu Pharmaceutical Co., Ltd. for the year 2010. It includes the director's attendance at board meetings, independent opinions on various company matters including audit firm changes, investments, related party transactions, internal control evaluations, and protection of minority shareholders' rights. The content is a comprehensive management and governance report on the director's duties and observations over the fiscal year 2010. It is not a financial statement report like an Annual Report (10-K) or Interim Report (IR), nor is it a brief announcement or certification. It is a management-related report focusing on board activities and oversight, fitting the category of Board/Management Information (MANG).
2011-02-25 Chinese
独立董事对公司2010年相关事项的独立意见
Audit Report / Information Classification · 95% confidence The document is an independent opinion report from independent directors regarding various company matters for the fiscal year 2010, including audit firm appointment for 2011, related party transactions, internal control self-assessment, securities investment, and external guarantees. It references regulatory guidelines and compliance with laws but does not contain full financial statements or detailed financial performance data. The document is a formal opinion and oversight report rather than a full annual report or audit report. It is not a short announcement or certification letter but a detailed independent opinion on governance and compliance matters related to the annual period. This fits best under Audit Report / Information (AR), as it includes audit-related opinions and internal control evaluations without being a full annual report (10-K). FY 2010
2011-02-25 Chinese
2010年年度审计报告
Audit Report / Information Classification · 100% confidence The document is titled as an audit report for the fiscal year 2010 of Beijing Shuanglu Pharmaceutical Co., Ltd. It includes an auditor's opinion, detailed financial statements such as balance sheet, income statement, cash flow statement, and statement of changes in equity. The presence of the auditor's report with registration number and the detailed financial data confirms this is a full audit report. The document length is substantial (15,000 characters), and it contains actual financial data and analysis, not just an announcement or certification. Therefore, it fits the category of Audit Report / Information (AR). FY 2010
2011-02-25 Chinese
董事会秘书工作制度（2011年2月）
Governance Information Classification · 95% confidence The document is titled as the 'Board Secretary Work System' of Beijing Shuanglu Pharmaceutical Co., Ltd. It details the duties, qualifications, appointment, and legal responsibilities of the company's board secretary. The content is a governance-related internal regulation document, focusing on board secretary roles and compliance with laws and stock exchange rules. There is no financial data, no report of financial results, no announcement of voting results, no legal proceedings, no capital changes, no earnings information, and no investor presentation. It is a governance practice document outlining internal rules and responsibilities related to corporate governance. Therefore, the most appropriate classification is Governance Information (CGR). The document length is 3823 characters, which is relatively short but contains substantive governance content, not just an announcement or notice, so it is not RPA or RNS. Confidence is high due to clear governance focus and absence of other report types.
2011-02-25 Chinese

Browse filings by year

23 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.